Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibody, chimeric antigen receptor and medicament targeting BCMA protein

A technology of chimeric antigen receptors and antibodies, applied in antibody mimics/stents, anti-tumor drugs, drug combinations, etc., can solve the problem of few types of antibodies

Active Publication Date: 2020-12-25
BIORAY LABORATORIES INC
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] However, there are currently fewer classes of antibodies against BCMA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibody, chimeric antigen receptor and medicament targeting BCMA protein
  • Antibody, chimeric antigen receptor and medicament targeting BCMA protein
  • Antibody, chimeric antigen receptor and medicament targeting BCMA protein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] 1 Phage library panning

[0062] Biotinylated hBCMA protein was used as the panning antigen for the fully human antibody library. First, block the phage antibody at room temperature with blocking solution (PBST / 5% skimmed milk powder) for 2 h, and the input amount of phage is 2×10 12 Phage, then add 10μg antigen, incubate at room temperature for 1h, add 50μl pre-blocked M-280 Streptavidin magnetic beads, incubate at room temperature for 30min.

[0063] First wash off the unbound phages with PBST, then elute the phages bound to the magnetic beads with 0.1M HCl-Glycine, then neutralize the eluate with Tris-HCl, and take part of the phages to infect the large intestine in the logarithmic growth phase Bacillus TG1, the collected phages were used for the next round of panning.

[0064] Gradually increase the screening intensity of each round, and stop panning when the enrichment degree reaches more than 100 times.

[0065] 2 Use phage Elisa to screen anti-BCMA single-ch...

Embodiment 2

[0094] Detect the binding force of the 4 BCMA antibodies obtained in Example 1, namely 2073, 2077, 2079 or 2082, to the hBCMA protein

[0095] Detection method:

[0096] (1) hBCMA protein coating, dilution from 1μg / ml, 3-fold serial dilution, a total of 8 gradients, the concentrations are 1μg / ml, 333ng / ml, 111ng / ml, 37ng / ml, 12.3ng / ml, 4.1 ng / ml, 1.37ng / ml, 0.45ng / ml, Costar-9018 microtiter plate was coated with 100μl hBCMA protein diluent, overnight at 4°C.

[0097] (2) After blocking with 3% BSA at room temperature for 2 hours, add the phage supernatant (10^10 pfu) corresponding to BCMA antibody 2073, 2077, 2079 or 2082, and incubate at room temperature for 2 hours.

[0098] (3) After washing away the unbound phage, add Ml3 Bacteriophage antibody (HRP), and incubate at 4°C for 1 hour. After washing, TMB chromogenic solution was added to develop color, and 2M HCl was used to terminate the reaction.

[0099] (4) Read at 450nm with a microplate reader, see the results figur...

Embodiment 3

[0102] Construction of chimeric antigen receptor expression vector

[0103] Build method:

[0104] (1) Whole gene synthesis: signal peptide (nucleotide sequence SEQ ID NO.66, amino acid sequence SEQ ID NO.73), BCMA antibody light chain variable region (light chain variable region of 2073, 2077, 2079 or 2082), Linker (nucleic acid sequence SEQ ID NO.67, amino acid sequence SEQ ID NO.74), BCMA antibody heavy chain variable region (heavy chain variable region of 2073, 2077, 2079 or 2082), hinge region (hinge) (nucleic acid sequence SEQ ID NO.74) ID NO.68, amino acid sequence SEQ ID NO.75), CD8α transmembrane domain (TM) (nucleic acid sequence SEQ ID NO.69, amino acid sequence SEQ ID NO.76), 4-1BB co-stimulatory signal transduction region (nucleic acid sequence SEQ ID NO.70, amino acid sequence SEQ ID NO.77) and CD3ζ signaling domain (nucleotide sequence SEQ ID NO.71, amino acid sequence SEQ ID NO.78). The above sequences are sequentially connected. Four kinds of chimeric antig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antibody, a chimeric antigen receptor and a medicament targeting BCMA protein, and relates to the technical field of cellular immunotherapy. The antibody has a heavy chain CDR region as shown in SEQ ID NO.22-24 and a light chain CDR region as shown in SEQ ID NO.30-32, or has a heavy chain CDR region as shown in SEQ ID NO.54-56 and a light chain CDR region as shown in SEQID NO.62-64. The antibody has a capacity of specifically combining with BCMA protein, and the chimeric antigen receptor T cells prepared from the antibody have a specific killing effect on target cells with positive BCMA protein and can be used for preparing a medicament for treating or preventing tumors.

Description

[0001] This application is a divisional application of an invention patent application with an application date of September 25, 2018, an application number of 201811117340.7, and an invention title of "Antibody, Chimeric Antigen Receptor and Drug Targeting BCMA Protein". technical field [0002] The invention relates to the technical field of cellular immunotherapy, in particular to an antibody targeting BCMA protein, a chimeric antigen receptor and a drug. Background technique [0003] Multiple myeloma (MM) is a malignant tumor characterized by massive proliferation of clonal plasma cells. Current MM treatments induce remission, but almost all patients eventually relapse and die. Although some monoclonal antibodies have shown promise in treating MM in preclinical studies and early clinical trials, there has been no consensus. Clearly, new immunotherapies for MM are clearly in great need, and the development of effective antigen-specific adoptive T cell therapy for this di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28C07K19/00C12N15/13C12N15/62C12N5/10C12N15/867G01N33/574G01N33/68A61K35/17A61K39/395A61P35/00
CPCA61P35/00A61K35/17C12N5/0636C07K14/7051C07K16/2878C07K2317/565C07K2319/02C07K2319/03C07K2319/33C07K2319/74C12N2510/00C12N15/86G01N33/57407G01N33/57492G01N33/6863C07K2317/622C12N2740/15043G01N2333/70578A61K2039/505
Inventor 晁瑞华刘明耀杜冰席在喜
Owner BIORAY LABORATORIES INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com